Fouladirad Saman, Bach Horacio
Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z, Canada.
Division of Infectious Diseases, University of British Columbia, Vancouver, BC V6T 1Z, Canada.
Microorganisms. 2021 Jan 13;9(1):165. doi: 10.3390/microorganisms9010165.
The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies endorsed by the World Health Organization for COVID-19, focusing only on supportive care. Treatment centers around symptom management, including oxygen therapy or invasive mechanical ventilation. Immunotherapy has the potential to play a role in the treatment of SARS-CoV-2. Monoclonal antibodies (mAbs), in particular, is a relatively new approach in the world of infectious diseases and has the benefit of overcoming challenges with serum therapy and intravenous immunoglobulins preparations. Here, we reviewed the articles published in PubMed with the purpose of summarizing the currently available evidence for the use of neutralizing antibodies as a potential treatment for coronaviruses. Studies reporting in vivo results were summarized and analyzed. Despite promising data from some studies, none of them progressed to clinical trials. It is expected that neutralizing antibodies might offer an alternative for COVID-19 treatment. Thus, there is a need for randomized trials to understand the potential use of this treatment.
2019年冠状病毒病（COVID-19）由新型冠状病毒SARS-CoV-2引起，于2019年12月在中国湖北省武汉市首次报告。截至2020年12月1日，这种病毒已导致全球报告6180万例病例。目前，世界卫生组织尚未批准针对COVID-19的明确疗法，仅侧重于支持性护理。治疗集中在症状管理，包括氧疗或有创机械通气。免疫疗法有可能在SARS-CoV-2的治疗中发挥作用。单克隆抗体（mAbs）尤其在传染病领域是一种相对较新的方法，具有克服血清疗法和静脉注射免疫球蛋白制剂挑战的优势。在此，我们查阅了发表在PubMed上的文章，目的是总结目前关于使用中和抗体作为冠状病毒潜在治疗方法的现有证据。对报告体内结果的研究进行了总结和分析。尽管一些研究有令人鼓舞的数据，但它们都没有进入临床试验阶段。预计中和抗体可能为COVID-19治疗提供一种替代方法。因此，需要进行随机试验以了解这种治疗方法的潜在用途。
